Axis 2
Studiedness
- Evidence amount
- 1.00
- Direction balance
- The direction of the study results has not been extracted.
- PMID records loaded
- 12
- Records after title/year deduplication
- 12
entity · release 2026-09-20
Saccharomyces boulardii CNCM I-745
Structured fields rendered from the release dataset. Unknown values retain a reason; price is outside GIS.
Across the corpus
How this organism is actually sold
- Forms
- Capsule: 1 · Powder: 1 · counted across the 2 of 2 published products whose label states a form
- Brands carrying it
- biocodex (2)
- Published product pages
- 2
Products
Published products carrying this organism
| Product | Printed CFU | Printed dose | Cost per day | Form | Gut Index Score |
|---|---|---|---|---|---|
| Biocodex Florastor | not printed | not printed | not observed | Capsule | 88.75 |
| Biocodex Florastor Kids Tutti-Frutti Flavor | not printed | not printed | not observed | Powder | 88.75 |
Containing labels3
Evidence amount1.00
Direction balanceThe direction of the study results has not been extracted.
Matched PubMed records
12 records (retracted records excluded; 0 retracted records match the query separately). PubMed query
Matched records include trials of multi-ingredient products; this is not a count of trials of this entity alone.
- 2025 · [Study on the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 in patients with small intestinal bacterial overgrowth associated with long-term use of proton pump inhibitors].
- 2024 · Randomised clinical trial: efficacy and safety of H. pylori eradication treatment with and without Saccharomyces boulardii supplementation.
- 2023 · Effectiveness of Saccharomyces Boulardii CNCM I-745 probiotic in acute inflammatory viral diarrhoea in adults: results from a single-centre randomized trial.
- 2023 · Impact of Saccharomyces boulardii CNCM I-745 on Bacterial Overgrowth and Composition of Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Patients: Results of a Randomized Pilot Study.
- 2022 · Randomized, direct comparison study of Saccharomyces boulardii CNCM I-745 versus multi-strained Bacillus clausii probiotics for the treatment of pediatric acute gastroenteritis.
- 2020 · Do Probiotics During In-Hospital Antibiotic Treatment Prevent Colonization of Gut Microbiota With Multi-Drug-Resistant Bacteria? A Randomized Placebo-Controlled Trial Comparing Saccharomyces to a Mixture of Lactobacillus, Bifidobacterium, and Saccharomyces.
- 2019 · Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial.
- 2017 · Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers.
- 2016 · Optimization of steroid injection intervals for prevention of stricture after esophageal endoscopic submucosal dissection: A randomized controlled trial.
- 2016 · A double-blinded randomized trial on growth and feeding tolerance with Saccharomyces boulardii CNCM I-745 in formula-fed preterm infants.
ClinicalTrials.gov
15 interventional studies. ClinicalTrials.gov query
This species has 6 tracked designations; this one appears on 3 labels (median 3.5).
Species and related strains
Axis 1 · inverted
Containing label versions
Showing 3 of 3 rows, ordered by Gut Index Score descending, then DSLD label ID. Download full CSV · Download full JSON.
| Brand | Product | DSLD | Gut Index Score | Strain named | Per-organism quantity | Potency basis | Versions |
|---|---|---|---|---|---|---|---|
| Biocodex | Florastor Kids Tutti-Frutti Flavor | 206738 | 88.75 | false | not printed for this organism | not stated | 1 |
| Biocodex | Florastor | 206744 | 88.75 | false | not printed for this organism | not stated | 2 |
| Biocodex | Florastor | 270390 | 88.75 | false | not printed for this organism | not stated | 2 |
Axis 3
Measurement integrity
Not a measurement product, so this axis does not apply.
Axis 4
Reddit mention panel
29 observed mentions · types {"bloating":8,"bowel":1,"gas":3,"improved":1,"side_effect":3}
Elsewhere in this release
Related pages
Compared side by side: Saccharomyces boulardii CNCM I-745 vs Biocodex Florastor
Findings computed over the whole corpus: Strain naming census · Label designation changes · Strain dose match · Stability literature gaps
Tools: DSLD product check · Unit value calculator
Citation
Cite this page
Ivitskiy, I. (2026). Saccharomyces boulardii CNCM I-745. Gut Registry, release 2026-09-20. Elanvale Ltd. https://gutregistry.com/s/saccharomyces-boulardii-cncm-i-745/
The underlying tables are published under CC BY 4.0: this page as CSV · as JSON · full release and data dictionary. Cell-level provenance names the source record and its observation date.
Citable atoms
Release claims
Saccharomyces boulardii CNCM I-745 appears on 3 of 13,330 labels in the NIH DSLD snapshot (Sep 2026), from 1 brands; tied with 39 designations by distinct label count.
3 / 13330 observed label versions · NIH DSLD snapshot Sep 2026 · entity.prevalence · checked 2026-09-20T00:00:00Z · snapshot b7633f7324373 of 3 containing labels in the NIH DSLD snapshot (Sep 2026) print a quantity for Saccharomyces boulardii CNCM I-745 (100.0%); 0 light records have quantities unavailable.
3 / 3 containing labels · NIH DSLD snapshot Sep 2026 · entity.quantity · checked 2026-09-20T00:00:00Z · snapshot b7633f73243712 PubMed records indexed as human randomized controlled trials match the published query (as of 2026-09-15). 12 records (retracted records excluded; 0 retracted records match the query separately).
12 / 12 loaded PMID records · NIH DSLD snapshot Sep 2026 · entity.evidence · checked 2026-09-20T00:00:00Z · snapshot b7633f73243715 interventional studies on ClinicalTrials.gov match the published query.
Published ClinicalTrials.gov query
15 / Not available in this release. interventional registry studies · NIH DSLD snapshot Sep 2026 · entity.registered_trials · checked 2026-09-20T00:00:00Z · snapshot b7633f7324370 of 2 SKUs containing Saccharomyces boulardii CNCM I-745 have a numeric price observation (0.0%) in the release accompanying the NIH DSLD snapshot Sep 2026.
0 / 2 containing SKUs · NIH DSLD snapshot Sep 2026 · entity.price · checked 2026-09-20T00:00:00Z · snapshot b7633f732437